Clinical Trial Update: Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years Earlier [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating immunogenicity and safety of GlaxoSmithKline's HZ/su vaccine in adults 65+ with or without prior Zostavax vaccination.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Herpes Zoster

Drugs mentioned

• HZ/su vaccine GSK1437173A (HZ/su vaccine GSK1437173A)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Herpes Zoster | Phase 3 | Status: COMPLETED | Results posted: 2017-09-26